C
Che-Hong Chen
Researcher at Stanford University
Publications - 89
Citations - 6702
Che-Hong Chen is an academic researcher from Stanford University. The author has contributed to research in topics: Aldehyde dehydrogenase & ALDH2. The author has an hindex of 33, co-authored 86 publications receiving 6052 citations. Previous affiliations of Che-Hong Chen include Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins.
TL;DR: Pitcher et al. as mentioned in this paper described the cloning of a cDNA encoding a 36-kDa protein (RACK1) that fulfills the criteria for RACKs.
Journal ArticleDOI
Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart
Che-Hong Chen,Grant R. Budas,Eric N. Churchill,Marie Helene Disatnik,Thomas D. Hurley,Daria Mochly-Rosen +5 more
TL;DR: Using an unbiased proteomic search, mitochondrial aldehyde dehydrogenase 2 (ALDH2) is identified as an enzyme whose activation correlates with reduced ischemic heart damage in rodent models and pharmacologic enhancement of ALDH2 activity may be useful for patients with wild-type or mutant AL DH2 who are subjected to cardiac ischemia.
Journal ArticleDOI
Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and ɛPKC
Leon Chen,Harvey S. Hahn,Guangyu Wu,Che-Hong Chen,Tamar Liron,Deborah Schechtman,Gabriele Cavallaro,Lucia Banci,Yiru Guo,Roberto Bolli,Gerald W. Dorn,Daria Mochly-Rosen +11 more
TL;DR: It is demonstrated that two related PKC isozymes have both parallel and opposing effects in the heart, indicating the danger in the use of therapeutics with nonselective isozyme inhibitors and activators.
Journal ArticleDOI
Targeting aldehyde dehydrogenase 2: new therapeutic opportunities
TL;DR: New research suggests that ALDH2 dysfunction may contribute to a variety of human diseases including cardiovascular diseases, diabetes, neurodegenerative diseases, stroke, and cancer, and epidemiological studies suggest a correlation between this inactivating mutation and increased propensity for common human pathologies.
Journal ArticleDOI
A Protein Kinase C Translocation Inhibitor as an Isozyme-selective Antagonist of Cardiac Function
TL;DR: These isozyme-selective translocation inhibitors provide novel tools to determine the function of individual PKC isozymes in intact cells.